Cervical cancer is the most commonly diagnosed cancer in 23 countries and is the leading cause of cancer death in 36 countries. According to WHO, a large majority of cervical cancer (more than 95%) is due to the human papillomavirus (HPV). HPV infection is widespread among women and men; an estimated 300 million women worldwide have an HPV infection yearly, and over 311,000 deaths annually. Different types of infection could lead to different diseases and cancers.

As suggested by WHO, HPV testing is an objective test that is simpler, prevents more pre-cancers and cancer, and saves more lives.

Bioperfectus 𝐒𝐢𝐦𝐩𝐥𝐢𝐞𝐝 𝟐𝟏 𝐆𝐞𝐧𝐨𝐭𝐲𝐩𝐢𝐧𝐠 𝐇𝐏𝐕-𝐃𝐍𝐀 𝐖𝐨𝐫𝐤𝐟𝐥𝐨𝐰 𝐟𝐨𝐫 𝐁𝐞𝐭𝐭𝐞𝐫 𝐏𝐫𝐞𝐯𝐞𝐧𝐭𝐢𝐧𝐠 𝐂𝐞𝐫𝐯𝐢𝐜𝐚𝐥 𝐂𝐚𝐧𝐜𝐞𝐫 embraces the WHO 90-70-90 target which could favor screening, diagnosis and treatment. Total PCR Solution supports detecting liquid-based cytology specimens and cervical swabs, offering effective treatment and preventing complications and further transmission.

Click here to download Bioperfectus Leaflet of 𝐒𝐢𝐦𝐩𝐥𝐢𝐞𝐝 𝟐𝟏 𝐆𝐞𝐧𝐨𝐭𝐲𝐩𝐢𝐧𝐠 𝐇𝐏𝐕-𝐃𝐍𝐀 𝐖𝐨𝐫𝐤𝐟𝐥𝐨𝐰 𝐟𝐨𝐫 𝐁𝐞𝐭𝐭𝐞𝐫 𝐏𝐫𝐞𝐯𝐞𝐧𝐭𝐢𝐧𝐠 𝐂𝐞𝐫𝐯𝐢𝐜𝐚𝐥 𝐂𝐚𝐧𝐜𝐞𝐫

Reference:

-Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021:71:209–49. doi:10.3322/caac.21660. 

-https://www.who.int/news-room/fact-sheets/detail/cervical-cancer

-https://stiwatch.org/hpv/

-https://www.who.int/news/item/19-08-2020-world-health-assembly-adopts-global-strategy-to-accelerate-cervical-cancer-elimination